Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
80
resultados
Última actualización
28/02/2026 [06:45:00]
Resultados 75 a 80 de 80
Resumen de: AU2024321532A1
Provided herein are methods for treating a disease or condition selected from the group consisting of cancer, autoimmune disease, graft or transplant-related condition, neurodegenerative disease, fibrotic-associated condition, ischemic-related conditions, infection (viral, parasitic or prokaryotic) and diseases associated with bone loss, the method comprising administering to a patient a therapeutically effective amount of carfilzomib or a pharmaceutically acceptable salt thereof at a dose volume of 10 mL/kg or higher. Also provided herein are methods for treating multiple myeloma in a patient, comprising administering to the patient a pharmaceutical composition comprising carfilzomib or a pharmaceutically acceptable salt thereof and an aqueous carrier, wherein the carfilzomib is administered at a dose volume of 2.5 mL/kg or higher and/or at a concentration of less than 2 mg/mL.
Resumen de: AU2024321683A1
Polyfluorinated thalidomide analogs have a structure according to formula I, wherein R is aliphatic. The compounds may be used to inhibit cancer cell proliferation and/or to treat subjects with cancer or an inflammatory process. In some aspects, the cancer is multiple myeloma. In certain aspects, the compounds are used to inhibit proliferation of drug-resistant multiple myeloma cells and/or to treat subjects with drug-resistant multiple myeloma.
Resumen de: US20260029402A1
The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has also been shown to be overexpressed in samples from patients with acute lymphoblastic leukemia. GARP therefore appears as a diagnostic marker, for monitoring T-cell malignancies, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of T-cell malignancies.
Resumen de: WO2026025099A1
Compositions and methods for control of DNMT1-mediated site-specific copy gains and genomic insertions associated with mixed lineage leukemia are provided.
Nº publicación: AU2026200174A1 29/01/2026
Solicitante:
REGENERON PHARMACEUTICALS INC
Regeneron Pharmaceuticals, Inc
Resumen de: AU2026200174A1
B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma. an a n
BOPI
Sede Electrónica
